Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol

Suzana S. Petanceska, Steven DeRosa, Ali Sharma, Nichole Diaz, Karen Duff, Steven G. Tint, Lorenzo M. Refolo, Miguel Pappolla

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Apolipoprotein E (ApoE) influences the risk of late onset Alzheimer's disease (AD) in an isoform-dependent manner, such that the presence of the apoE ε4 allele increases the risk of AD while the presence of the apoE ε2 allele appears to be protective. Although a number of ApoE functions are isoform dependent and may underlie the "risk factor" activity of AD, its ability to bind amyloid β peptides and influence their clearance and/ or deposition has gained strong experimental support. Evidence suggests that in addition to genotype, increased ApoE transcription can contribute to AD risk. There is growing evidence in support of the hypothesis that disrupted cholesterol metabolism is an early risk factor for AD. Studies in animal models have shown that chronic changes in cholesterol metabolism associate with changes in brain Aβ accumulation, a process instrumental for establishing AD pathology. ApoE mediates cholesterol homeostasis in the body and is a major lipid carrier in brain. As such, its expression in the periphery and in brain changes in response to changes in cholesterol metabolism. Here, we used a transgenic mouse model of Alzheimer's amyloidosis to examine whether the diet-induced or pharmacologically induced changes in plasma cholesterol that result in altered brain amyloidosis also affect ApoE content in liver and in brain. We found that chronic changes in total cholesterol in plasma lead to changes in ApoE mRNA levels in brain. We also found that cholesterol loading of primary glial cells increases cellular and secreted ApoE levels and that long-term treatment of astrocy tes and microglia with statins leads to a decrease in the cellular and/or secreted ApoE. These observations suggest that disrupted cholesterol metabolism may increase the risk of developing AD in part due to the effect of cholesterol on brain ApoE expression.

Original languageEnglish (US)
Pages (from-to)395-406
Number of pages12
JournalJournal of Molecular Neuroscience
Volume20
Issue number3
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Apolipoproteins E
Cholesterol
Modulation
Pharmacology
Brain
Alzheimer Disease
Metabolism
Amyloidosis
Protein Isoforms
Alleles
Plasmas
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Aptitude
Microglia
Pathology
Transcription
Nutrition
Amyloid
Neuroglia
Liver

Keywords

  • Alzheimer's disease
  • ApoE
  • Cholesterol
  • Statin
  • Transgenic mice

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry
  • Genetics

Cite this

Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol. / Petanceska, Suzana S.; DeRosa, Steven; Sharma, Ali; Diaz, Nichole; Duff, Karen; Tint, Steven G.; Refolo, Lorenzo M.; Pappolla, Miguel.

In: Journal of Molecular Neuroscience, Vol. 20, No. 3, 2003, p. 395-406.

Research output: Contribution to journalArticle

Petanceska, Suzana S. ; DeRosa, Steven ; Sharma, Ali ; Diaz, Nichole ; Duff, Karen ; Tint, Steven G. ; Refolo, Lorenzo M. ; Pappolla, Miguel. / Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol. In: Journal of Molecular Neuroscience. 2003 ; Vol. 20, No. 3. pp. 395-406.
@article{6e2b7e2e02dc4edd977ee8fde82ff662,
title = "Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol",
abstract = "Apolipoprotein E (ApoE) influences the risk of late onset Alzheimer's disease (AD) in an isoform-dependent manner, such that the presence of the apoE ε4 allele increases the risk of AD while the presence of the apoE ε2 allele appears to be protective. Although a number of ApoE functions are isoform dependent and may underlie the {"}risk factor{"} activity of AD, its ability to bind amyloid β peptides and influence their clearance and/ or deposition has gained strong experimental support. Evidence suggests that in addition to genotype, increased ApoE transcription can contribute to AD risk. There is growing evidence in support of the hypothesis that disrupted cholesterol metabolism is an early risk factor for AD. Studies in animal models have shown that chronic changes in cholesterol metabolism associate with changes in brain Aβ accumulation, a process instrumental for establishing AD pathology. ApoE mediates cholesterol homeostasis in the body and is a major lipid carrier in brain. As such, its expression in the periphery and in brain changes in response to changes in cholesterol metabolism. Here, we used a transgenic mouse model of Alzheimer's amyloidosis to examine whether the diet-induced or pharmacologically induced changes in plasma cholesterol that result in altered brain amyloidosis also affect ApoE content in liver and in brain. We found that chronic changes in total cholesterol in plasma lead to changes in ApoE mRNA levels in brain. We also found that cholesterol loading of primary glial cells increases cellular and secreted ApoE levels and that long-term treatment of astrocy tes and microglia with statins leads to a decrease in the cellular and/or secreted ApoE. These observations suggest that disrupted cholesterol metabolism may increase the risk of developing AD in part due to the effect of cholesterol on brain ApoE expression.",
keywords = "Alzheimer's disease, ApoE, Cholesterol, Statin, Transgenic mice",
author = "Petanceska, {Suzana S.} and Steven DeRosa and Ali Sharma and Nichole Diaz and Karen Duff and Tint, {Steven G.} and Refolo, {Lorenzo M.} and Miguel Pappolla",
year = "2003",
doi = "10.1385/JMN:20:3:395",
language = "English (US)",
volume = "20",
pages = "395--406",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol

AU - Petanceska, Suzana S.

AU - DeRosa, Steven

AU - Sharma, Ali

AU - Diaz, Nichole

AU - Duff, Karen

AU - Tint, Steven G.

AU - Refolo, Lorenzo M.

AU - Pappolla, Miguel

PY - 2003

Y1 - 2003

N2 - Apolipoprotein E (ApoE) influences the risk of late onset Alzheimer's disease (AD) in an isoform-dependent manner, such that the presence of the apoE ε4 allele increases the risk of AD while the presence of the apoE ε2 allele appears to be protective. Although a number of ApoE functions are isoform dependent and may underlie the "risk factor" activity of AD, its ability to bind amyloid β peptides and influence their clearance and/ or deposition has gained strong experimental support. Evidence suggests that in addition to genotype, increased ApoE transcription can contribute to AD risk. There is growing evidence in support of the hypothesis that disrupted cholesterol metabolism is an early risk factor for AD. Studies in animal models have shown that chronic changes in cholesterol metabolism associate with changes in brain Aβ accumulation, a process instrumental for establishing AD pathology. ApoE mediates cholesterol homeostasis in the body and is a major lipid carrier in brain. As such, its expression in the periphery and in brain changes in response to changes in cholesterol metabolism. Here, we used a transgenic mouse model of Alzheimer's amyloidosis to examine whether the diet-induced or pharmacologically induced changes in plasma cholesterol that result in altered brain amyloidosis also affect ApoE content in liver and in brain. We found that chronic changes in total cholesterol in plasma lead to changes in ApoE mRNA levels in brain. We also found that cholesterol loading of primary glial cells increases cellular and secreted ApoE levels and that long-term treatment of astrocy tes and microglia with statins leads to a decrease in the cellular and/or secreted ApoE. These observations suggest that disrupted cholesterol metabolism may increase the risk of developing AD in part due to the effect of cholesterol on brain ApoE expression.

AB - Apolipoprotein E (ApoE) influences the risk of late onset Alzheimer's disease (AD) in an isoform-dependent manner, such that the presence of the apoE ε4 allele increases the risk of AD while the presence of the apoE ε2 allele appears to be protective. Although a number of ApoE functions are isoform dependent and may underlie the "risk factor" activity of AD, its ability to bind amyloid β peptides and influence their clearance and/ or deposition has gained strong experimental support. Evidence suggests that in addition to genotype, increased ApoE transcription can contribute to AD risk. There is growing evidence in support of the hypothesis that disrupted cholesterol metabolism is an early risk factor for AD. Studies in animal models have shown that chronic changes in cholesterol metabolism associate with changes in brain Aβ accumulation, a process instrumental for establishing AD pathology. ApoE mediates cholesterol homeostasis in the body and is a major lipid carrier in brain. As such, its expression in the periphery and in brain changes in response to changes in cholesterol metabolism. Here, we used a transgenic mouse model of Alzheimer's amyloidosis to examine whether the diet-induced or pharmacologically induced changes in plasma cholesterol that result in altered brain amyloidosis also affect ApoE content in liver and in brain. We found that chronic changes in total cholesterol in plasma lead to changes in ApoE mRNA levels in brain. We also found that cholesterol loading of primary glial cells increases cellular and secreted ApoE levels and that long-term treatment of astrocy tes and microglia with statins leads to a decrease in the cellular and/or secreted ApoE. These observations suggest that disrupted cholesterol metabolism may increase the risk of developing AD in part due to the effect of cholesterol on brain ApoE expression.

KW - Alzheimer's disease

KW - ApoE

KW - Cholesterol

KW - Statin

KW - Transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=0642370860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642370860&partnerID=8YFLogxK

U2 - 10.1385/JMN:20:3:395

DO - 10.1385/JMN:20:3:395

M3 - Article

C2 - 14501024

AN - SCOPUS:0642370860

VL - 20

SP - 395

EP - 406

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 3

ER -